Secreotory Leukocyte Protease Inhibitor Regulates Bone Formation via RANKL, OPG, and Runx2 in Rat Periodontitis and MC3T3-E1 Preosteoblast
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Secretory leukocyte protease inhibitor (SLPI) protects tissues from proteases and promotes cell proliferation and healing. SLPI also reduces periodontal inflammation and alveolar bone resorption by inhibiting proinflammatory cytokine expression in rat periodontal tissues and osteoblasts. However, little is known of the role of SLPI in the expression of osteoclast regulatory factors from osteoblasts, which are crucial for the interaction between osteoblasts and osteoclasts. Therefore, we aimed to determine the effects of SLPI on the regulation of osteoclasts and osteoblasts in LPS-treated alveolar bone and osteoblasts. Methods: Periodontitis was induced in rats using LPS. After each LPS injection, SLPI was injected into the same area. Immu-nohistochemical analysis was performed with antibodies against SLPI, RANKL, OPG, and Runx2 in the periodontal tissue. RT-PCR and western blotting were performed to determine the expression levels of SLPI, RANKL, OPG, and Runx2 in LPS- and SLPI/LPS-treated MC3T3-E1 cells. SLPI/LPS-treated MC3T3-E1 cells were also stained with Alizarin Red S. Results: Immunohistochemical analysis showed that the expression levels of SLPI, OPG, and Runx2 were higher while that of RANKL was lower in the LPS/SLPI group relative to those in the LPS group. The mRNA and protein expression of SLPI, OPG, and Runx2 was higher in SLPI/LPS/MC3T3-E1 cells than in LPS/MC3T3-E1 cells, and RANKL expression was lower. During differentiation, OPG and Runx2 protein levels were higher whereas RANKL levels were lower in SLPI/LPS/MC3T3-E1 than in LPS/MC3T3-E1 cells on days 0, 4, 7, and 10. In addition, mineralization and matrix deposition were higher in SLPI/LPS/MC3T3-E1 than in LPS/MC3T3-E1 on days 7 and 10. SLPI decreased RANKL expression in LPS-treated alveolar bone and osteoblasts but increased the expression of OPG and Runx2. Conclusion: SLPI can be considered as a regulatory molecule that indirectly regulates osteoclast activation via osteoblasts and promotes osteoblast differentiation.
Abstract
Background: Secretory leukocyte protease inhibitor (SLPI) protects tissues from proteases and promotes cell proliferation and healing. SLPI also reduces periodontal inflammation and alveolar bone resorption by inhibiting proinflammatory cytokine expression in rat periodontal tissues and osteoblasts. However, little is known of the role of SLPI in the expression of osteoclast regulatory factors from osteoblasts, which are crucial for the interaction between osteoblasts and osteoclasts. Therefore, we aimed to determine the effects of SLPI on the regulation of osteoclasts and osteoblasts in LPS-treated alveolar bone and osteoblasts. Methods: Periodontitis was induced in rats using LPS. After each LPS injection, SLPI was injected into the same area. Immu-nohistochemical analysis was performed with antibodies against SLPI, RANKL, OPG, and Runx2 in the periodontal tissue. RT-PCR and western blotting were performed to determine the expression levels of SLPI, RANKL, OPG, and Runx2 in LPS- and SLPI/LPS-treated MC3T3-E1 cells. SLPI/LPS-treated MC3T3-E1 cells were also stained with Alizarin Red S. Results: Immunohistochemical analysis showed that the expression levels of SLPI, OPG, and Runx2 were higher while that of RANKL was lower in the LPS/SLPI group relative to those in the LPS group. The mRNA and protein expression of SLPI, OPG, and Runx2 was higher in SLPI/LPS/MC3T3-E1 cells than in LPS/MC3T3-E1 cells, and RANKL expression was lower. During differentiation, OPG and Runx2 protein levels were higher whereas RANKL levels were lower in SLPI/LPS/MC3T3-E1 than in LPS/MC3T3-E1 cells on days 0, 4, 7, and 10. In addition, mineralization and matrix deposition were higher in SLPI/LPS/MC3T3-E1 than in LPS/MC3T3-E1 on days 7 and 10. SLPI decreased RANKL expression in LPS-treated alveolar bone and osteoblasts but increased the expression of OPG and Runx2. Conclusion: SLPI can be considered as a regulatory molecule that indirectly regulates osteoclast activation via osteoblasts and promotes osteoblast differentiation.
참고문헌 (31)
- Lee JW, "Rosmarinic acid exerts an antiosteoporotic effect in the RANKL-induced mouse model of bone loss by promotion of osteoblastic differentiation and inhibition of osteoclastic differentiation", Mol Nutr Food Res, 59, pp.386~400 (2015)[DOI]
- Suda T, "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families", Endocr Rev, 20, pp.345~357 (1999)[DOI]
- Graves D, "Cytokines that promote periodontal tissue destruction", J Periodontol, 79(8 Suppl), pp.1585~1591 (2008)[DOI]
- Inubushi T, "Molecular mechanisms of the inhibitory effects of bovine lactoferrin on lipopolysaccharide-mediated osteoclastogenesis", J Biol Chem, 287, pp.23527~23536 (2012)[DOI]
- Yasuda H, "Identity of osteoclastogenesis inhibitory factor(OCIF)and osteoprotegerin(OPG) : a mechanism by which OPG", OCIF inhibits osteoclastogenesis in vitro, 1998, pp.139, 1329~1337
- Xu Y, "Inhibition of bone metastasis from breast carcinoma by rosmarinic acid", Planta Med, 76, pp.956~962 (2010)[DOI]
- Wachi T, "Release of titanium ions from an implant surface and their effect on cytokine production related to alveolar bone resorption", Toxicology, 327, pp.1~9 (2015)[DOI]
- Lacey DL, "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", Cell, 93, pp.165~176 (1998)[DOI]
- Deyama Y, "Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells", Biochem Biophys Res Commun, 274, pp.249~254 (2000)[DOI]
- Simonet WS, "Osteoprotegerin : a novel secreted protein involved in the regulation of bone density", Cell, 89, pp.309~319 (1997)[DOI]
- Komori T, "Regulation of osteoblast differentiation by Runx2", Adv Exp Med Biol, 658, pp.43~49 (2010)[DOI]
- Komori T, "Regulation of osteoblast differentiation by transcription factors", J Cell Biochem, 99, pp.1233~1239 (2006)[DOI]
- Jeong SJ, "660 nm red LED induces secretory leukocyte protease inhibitor(SLPI)in lipopolysaccharide-stimulated Raw264. 7 cell", J Nanosci Nanotechnol, 15, pp.5610~5616 (2015)[DOI]
- Choi BD, "Temporal induction of secretory leukocyte protease inhibitor(SLPI)in odontoblasts by lipopolysaccharide and wound infection", J Endod, 35, pp.997~1002 (2009)[DOI]
- Jeong JO, "Function of secretory leukocyte protease inhibitor(SLPI)in odontoblast during mouse tooth development", J Nanosci Nanotechnol, 15, pp.120~124 (2015)[DOI]
- Jeong SJ, "Secretory leukocyte protease inhibitor(SLPI)increases focal adhesion in MC3T3osteoblast on titanium surface", J Nanosci Nanotechnol, 15, pp.200~204 (2015)[DOI]
- Choi BD, "Secretory leukocyte protease inhibitor promotes differentiation and mineralization of MC3T3-E1 preosteoblasts on a titanium surface", Mol Med Rep, 14, pp.1241~1246 (2016)[DOI]
- 이승연, "Secretory leukocyte protease inhibitor reduces inflammation and alveolar bone resorption in LPS-induced periodontitis in rats and in MC3T3-E1 preosteoblasts", Animal Cells and Systems, 20(6), pp.344~352 (2016), 한국통합생물학회[DOI]
- Lindemann RA, "Production of interleukin-1 and tumor necrosis factor by human peripheral monocytes activated by periodontal bacteria and extracted lipopolysaccharides", J Dent Res, 67, pp.1131~1135 (1988)[DOI]
- Gabay C, "IL-1 pathways in inflammation and human diseases", Nat Rev Rheumatol, 6, pp.232~241 (2010)[DOI]
- Hiemstra PS, "Novel roles of protease inhibitors in infection and inflammation", Biochem Soc Trans, 30, pp.116~120 (2002)[DOI]
- Williams SE, "SLPI and elafin: one glove, many fingers", Clin Sci (Lond), 110, pp.21~35 (2006)[DOI]
- Hofbauer LC, "The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption", J Bone Miner Res, 15, pp.2~12 (2000)[DOI]
- 정문진, "Effect of rosmarinic acid on differentiation and mineralization of MC3T3-E1 osteoblastic cells on titanium surface", Animal Cells and Systems, 25(1), pp.46~55 (2021), 한국통합생물학회[DOI]
- Gilbert L, "Expression of the osteoblast differentiation factor RUNX2(Cbfa1", AML3, J Biol Chem, pp.2002, 277[DOI]
- Chen X, "Osteoblast-osteoclast interactions", Connect Tissue Res, 59, pp.99~107 (2018)[DOI]
- Siddiqui S, "Genistein contributes to cell cycle progression and regulates oxidative stress in primary culture of osteoblasts along with osteoclasts attenuation", BMC Complement Med Ther, 20, pp.277~ (2020)[DOI]
- Lai K, "Activation of Nell-1 in BMSC sheet promotes implant osseointegration through regulating Runx2", Osterix axis, 2020, pp.8, 868~
- Yu SB, "Cordycepin accelerates osteoblast mineralization and attenuates osteoclast differentiation in vitro", Evid Based Complement Alternat Med, 2018, pp.5892957~ (2018)[DOI]
- Kim JH, "Leonurus sibiricus L. ethanol extract promotes osteoblast differentiation and inhibits osteoclast formation", Int J Mol Med, 44, pp.913~926 (2019)[DOI]
- Kruger EA, "In vitro mineralization of human mesenchymal stem cells on threedimensional type I collagen versus PLGA scaffolds : a comparative analysis", Plast Reconstr Surg, 127, pp.2301~2311 (2011)[DOI]